Related Experiment Video
Updated: Jun 17, 2025

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
Published on: February 18, 2022
Management of Chronic Heart Failure with Reduced Ejection Fraction
Brandon Williamson1, Carl Tong2
1From the Texas A&M University Health Science Center, Bryan, TX (BW); Texas A&M University Health Science Center, Bryan, TX (CT). Bwilliamson@tamu.edu.
None:
Heart failure with reduced ejection fraction (HFrEF) is a commonly seen clinical entity in the family physician's practice. This clinical review focuses on the pharmacologic management of chronic HFrEF. Special attention is paid to the classification of heart failure and the newest recommendations from the American Heart Association concerning the use of guideline-directed medical therapy. β blockers, ACE inhibitors, ARBs, mineralocorticoid receptor antagonists are discussed in detail. The new emphasis on sacubitril-valsartan and SGLT2i's as therapies for HFrEF are reviewed, followed by a brief discussion of more advanced therapies and comorbidity management.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Pathophysiology of Heart Failure
Heart Failure Drugs: Diuretics
Heart Failure Drugs: β-Blockers
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation

